These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350 [TBL] [Abstract][Full Text] [Related]
68. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574 [TBL] [Abstract][Full Text] [Related]
69. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. Fogarty E; Schmitz S; Tubridy N; Walsh C; Barry M Mult Scler Relat Disord; 2016 Sep; 9():23-30. PubMed ID: 27645339 [TBL] [Abstract][Full Text] [Related]
70. Glatiramer: new preparation. No place in multiple sclerosis. Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208 [TBL] [Abstract][Full Text] [Related]
71. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Carrá A; Onaha P; Luetic G; Burgos M; Crespo E; Deri N; Halfon M; Jaacks G; López A; Sinay V; Vrech C Eur J Neurol; 2008 Apr; 15(4):386-93. PubMed ID: 18353125 [TBL] [Abstract][Full Text] [Related]
72. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. Koch-Henriksen N; Sørensen PS Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828 [TBL] [Abstract][Full Text] [Related]
73. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659 [TBL] [Abstract][Full Text] [Related]
74. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Jeffery DR; Chepuri N; Durden D; Burdette J Mult Scler; 2005 Jun; 11(3):296-301. PubMed ID: 15957510 [TBL] [Abstract][Full Text] [Related]
75. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. Rudick RA Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808 [TBL] [Abstract][Full Text] [Related]
76. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099 [TBL] [Abstract][Full Text] [Related]
77. [Recent advances in the pathogenesis and immunotherapy of multiple sclerosis]. Gold R; Rieckmann P Nervenarzt; 2007 Sep; 78 Suppl 1():15-24; quiz 25. PubMed ID: 17668159 [TBL] [Abstract][Full Text] [Related]
78. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis]. Cendrowski W Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611 [TBL] [Abstract][Full Text] [Related]
79. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group. Liu C; Blumhardt LD J Neurol Sci; 2000 Dec; 181(1-2):33-7. PubMed ID: 11099709 [TBL] [Abstract][Full Text] [Related]